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Pituitary adenylate cyclase-activating polypeptide (PACAP) is a potent insulinotropic G-
protein-coupled receptor ligand, for which morphoregulative roles in pancreatic islets have
recently been suggested. Here, we evaluated the effects of pancreatic overexpression
of PACAP on morphometric changes of islets in a severe type II diabetes model. Follow-
ing cross-breeding of obese-diabetic model KKAy mice with mice overexpressing PACAP
in their pancreatic β-cells, the resulting KKAy mice with or without PACAP transgene
(PACAP/+:Ay/+ or Ay/+ mice) were fed with a high-fat diet up to the age of 11 months.
Pancreatic sections from 5- to 11-month-old littermates were examined. Histomorphome-
tric analyses revealed significant suppression of islet mass expansion in PACAP/+:Ay/+
mice compared with Ay/+ mice at 11 months, but no significant difference between
PACAP/+ and +/+ (wild-type) mice, as previously reported. The suppressed islet mass
in PACAP/+:Ay/+mice was due to a decrease in islet density but not islet size. In addition,
the density of tiny islets (<0.001 mm2) and of insulin-positive clusters in ductal structures
were markedly decreased in PACAP/+:Ay/+ mice compared with Ay/+ mice at 5 months
of age. In contrast, PACAP overexpression caused no significant effects on the level of
aldehyde-fuchsin reagent staining (a measure of β-cell granulation) or the volume and local-
ization of glucagon-positive cells in the pancreas.These results support previously reported
inhibitory effects of PACAP on pancreatic islet mass expansion, and suggest it has per-
sistent suppressive effects on pancreatic islet density which may be related with ductal
cell-associated islet neogenesis in type II diabetes.
Keywords: β cells, KKAy mice, high-fat diet, pituitary adenylate cyclase-activating polypeptide, islet neogenesis,
type 2 diabetes
INTRODUCTION
Pituitary adenylate cyclase-activating polypeptide (PACAP) is
an extraordinarily potent insulinotropic peptide (Yada et al.,
1994) belonging to the vasoactive intestinal polypeptide
(VIP)/secretin/glucagon superfamily,which also includes glucagon-
like peptide-1 (GLP-1) and glucose-dependent insulinotropic pep-
tide (GIP) (Vaudry et al., 2009). PACAP and its receptors [PACAP-
specific PAC1,andVIP-sharedVPAC1 andVPAC2 receptors,which
belong to the class B (class II) G-protein-coupled receptor fam-
ily] are highly expressed in neural elements, suggesting that it
acts as a neurotransmitter and neuromodulator both in brain and
peripheral tissues (Vaudry et al., 2009). There have been numer-
ous studies on PACAP, in which its metabolic effects have been
well documented (Ahrén, 2008; Vaudry et al., 2009). For example,
PACAP has been shown to reduce food intake, increase glucose
uptake in adipocytes by potentiating insulin action, stimulate the
secretion of glucagon from the pancreas and norepinephrine from
the adrenal medulla, in addition to its insulinotropic activities in
the pancreas. Based on these reports, several studies have eval-
uated the therapeutic potential of agonists or antagonists of the
PACAP/VIP receptors (including PACAP and/or VIP themselves),
and an inhibitor of dipeptidyl peptidase-4 (DPP-4), a common
degradation enzyme for PACAP,VIP, GIP, and GLP-1, for the treat-
ment of metabolic syndrome, including diabetes mellitus (Ahrén,
2008, 2009; Verspohl, 2009; Chapter et al., 2010). DPP-4 inhibitors
are currently used as anti-diabetic agents (Holst, 2006; Verspohl,
2009).
As a potential cure for diabetes mellitus, a disease resulting from
insulin insufficiency, recent studies have raised the possibility of
the enhancement of endogenous β-cell mass, and transplantation
of islets themselves, as a novel therapeutic strategy (Vaithilingam
et al., 2008; Hanley, 2009; Verspohl, 2009; Dalle et al., 2011).
With respect to this possibility, some studies have revealed that
PACAP can stimulate β-cell proliferation and suppress the effects
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of harmful exogenous insults on the β-cell (Yamamoto et al., 2003;
Nakata et al., 2010), although it has also been shown that PACAP
has inhibitory effects on the pancreatic islet mass (see our review
article, Sakurai et al., 2011). Recent studies using animal mod-
els in which PACAP/VIP signaling molecules have been knocked
out have shown an increased mean islet area in PACAP-KO mice
(Tomimoto et al., 2008) and altered islet architecture inVPAC1-KO
mice (Fabricius et al., 2011), although no significant defects have
been reported in VIP-KO mouse islets (Martin et al., 2010). These
results suggest possible roles of PACAP/VIP signaling in islet mor-
phoregulation, although it remains unknown how they regulate
islet morphology, particularly in the case of type II diabetes.
Approximately a decade ago, we generated mice either lacking
PACAP (Hashimoto et al., 2001) or overexpressing PACAP specifi-
cally in pancreatic β-cells (PACAP/+mice; Yamamoto et al., 2003).
To explore the long-term effects of PACAP in type II diabetes,
we cross-bred PACAP/+ mice with agouti yellow KKAy mice, an
obesity-induced type II diabetic model (Iwatsuka et al., 1970),
and showed that pancreatic PACAP overexpression attenuated
hyperinsulinemia and islet hyperplasia in KKAy mice, without
any alteration of plasma glucose, glucose tolerance, or insulin
tolerance (Tomimoto et al., 2004). Since the mild and delayed-
onset hyperglycemia in KKAy mice (Srinivasan and Ramarao,
2007) might mask the effects of PACAP in this model, we recently
re-examined the phenotypic effects of PACAP overexpression in
KKAy mice fed a high-fat diet (HFD) (Sakurai et al., 2012). The
results showed that HFD feeding of KKAy mice induced severe,
early-onset diabetes, but caused an unexpected recovery from
hyperglycemia between 6 and 11 months of age, partly due to
simultaneous (6–10 months of age) hyperinsulinemia. We also
found that PACAP overexpression retained its previously observed
suppressive effects, particularly those relating to hyperinsulinemia,
in HFD-fed KKAy mice (Sakurai et al., 2012), however there has
been no reported morphological information on the pancreatic
islets of this model.
In the present study, we performed several morphometrical
analyses of the islet phenotype of HFD-fed KKAy mice, includ-
ing staining with hematoxylin-eosin (HE), aldehyde-fuchsin (AF),
and anti-insulin and anti-glucagon antibodies. Here, we used
PACAP/+mice to evaluate the direct and local action of PACAP on
the islet morphology, since PACAP can exert pleiotropic actions
on adipocyte and adrenal medulla in addition to islets and sec-
ondary affect islets. The results obtained show that PACAP retains
its inhibitory effects on pancreatic islet mass expansion, and pro-
vide a range of evidence suggesting that pancreatic PACAP affects
ductal cell-associated islet neogenesis.
MATERIALS AND METHODS
ANIMALS, DIETS, AND REAGENTS
All animal care and handling procedures were approved by the
Institutional Animal Care and Use Committee of Osaka Univer-
sity. Mice were housed in a temperature-, humidity-, and light-
controlled room with a 12-h light/12-h dark cycle (lights on at
08:00 a.m.) and allowed free access to water and chow. Mating,
genotyping, and feeding procedures were as previously described
(Sakurai et al., 2012). In brief, F1 mice (+/+, PACAP/+, Ay/+,
and Ay/+:PACAP/+) were obtained by mating female transgenic
mice overexpressing PACAP in their pancreatic β cells (Yamamoto
et al., 2003) with male KKAy mice (KK-Ay/Ta mice, CLEA Japan
Inc., Tokyo, Japan). F1 males were individually housed after geno-
typing and weaning, and males with the Ay allele (Ay/+ and
Ay/+:PACAP/+) were fed with an HFD (HFD-32, CLEA Japan,
Tokyo, Japan) from 4 weeks of age, while the other males continued
on a normal diet (ND) (DC-8, CLEA Japan). These diets con-
tain either 11.8% (DC-8) or 56.7% (HFD-32) of energy derived
from fat.
HISTOCHEMISTRY
From each deeply anesthetized mouse, the pancreas was removed,
weighed, and immediately fixed in 4% paraformaldehyde in phos-
phate buffered saline solution. Samples were embedded in paraf-
fin, and 5µm sections were prepared for HE or AF staining, or
immunohistochemical staining with anti-insulin (N1542, DAKO,
Carpinteria, CA, USA) or anti-glucagon (N1541, DAKO) antibod-
ies, in which signals were visualized using the diaminobenzidine
method and were counterstained with cresyl violet. To investi-
gate the architectural changes in the islets, two serial sections were
prepared for immunostaining with anti-insulin and anti-glucagon
antibodies, respectively.
MORPHOMETRY
Stained sections were photographed using a BIOREVO BZ-9000
microscope (Keyence, Japan), and morphometrical parameters
were examined as follows. In HE-stained sections (n= 4–6 for 5-
month-old mice, and n= 7–9 for 11-month-old mice), total islet
number, size of each islet, and total pancreatic area were counted
or measured, and analyzed as previously described (Tomimoto
et al., 2004). Briefly, in each section from four F1 groups, the mean
islet size was determined by averaging the size of each islet, and
the islet density by dividing total islet number by total pancreatic
area (mm2). Islet mass was calculated by multiplying the pancreas
weight by the relative islet area per pancreas. The density per mm2
of total pancreatic area, in addition to the frequency of the six
groups of optical islet size (<0.003, 0.003–0.01, 0.01–0.03, 0.03–
0.1, 0.1–0.3, and >0.3 mm2), was also determined. In AF-stained
sections (n= 5 for 5-month-old mice, and n= 3 for 11-month-
old mice), blinded observers evaluated the AF reagent staining in
each islet of four F1 groups. In sections stained with anti-insulin
or anti-glucagon antibodies (n= 4 for each group), the positive
area and the size of each insulin-positive cluster were measured
using ImageJ software (version 1.30, http://rsb.info.nih.gov/ij).
The number of insulin-positive clusters, and of glucagon cell-
infiltrated islets (which exhibit glucagon-positive cells inside of
islets as indicated by arrows in Figure 2B), were also counted and
analyzed.
PLASMA INSULIN LEVEL IN AN INTRAPERITONEAL GLUCOSE
TOLERANCE TEST
Two milligrams per kilogram glucose was intraperitoneally
injected to each mouse after a 14-h food deprivation as described
(Sakurai et al., 2012). Plasma samples were prepared just before
(time 0) and at 10, 30, 60, 90, and 120 min after glucose load, and
the insulin level in the samples was examined by a mouse insulin
enzyme-linked immunosorbent assay (Morinaga, Tokyo, Japan).
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DATA ANALYSIS AND STATISTICS
All data are expressed as mean± standard error of the mean. Sta-
tistical evaluation was carried out using KaleidaGraph software
(HULINKS, Tokyo, Japan). The statistical significance of differ-
ences was assessed using two-way ANOVA followed by the Tukey–
Kramer test, χ2 test, and Student’s un-paired t -test. Differences
with P < 0.05 were considered significant.
RESULTS
EFFECTS ON SIZE AND DENSITY OF ISLETS
In KKAy mice fed with a ND, we previously showed that pancreatic
PACAP overexpression markedly suppresses the increase of mean
islet size and of islet density (Tomimoto et al., 2004). Contrary
to these observations, HE-stained pancreatic sections from 11-
month-old HFD-fed KKAy mice showed that not only Ay/+mice,
but also Ay/+:PACAP/+mice, exhibited a clear islet enlargement
(Figure 1A). Quantitative analyses indicated that the mean size was
significantly increased in both groups compared with their respec-
tive controls, but no significant difference was observed between
Ay/+ and Ay/+:PACAP/+ mice at either 5 or 11 months of age
(Figure 1B, upper graphs). In contrast, a significant increase in
inlet density was observed in Ay/+ but not in Ay/+:PACAP/+
mice, and the density in Ay/+:PACAP/+ mice was significantly
suppressed compared with Ay/+mice at both 5 and 11 months of
age (Figure 1B, middle graphs). With respect to islet mass, there
was a large increase in Ay/+mice (e.g., it was 22-fold higher than
+/+ mice at 11 months of age; Figure 1B, lower graphs). In a
model showing such remarkable islet mass expansion, pancreatic
PACAP overexpression caused a 30% reduction in islet mass at
11 months of age (Figure 1B, lower right graph). Taken together
with our previous results in ND-fed KKAy mice (Tomimoto et al.,
2004), these results indicate that the inhibitory effects of PACAP
on islet density are retained, but those influencing islet size are
lost, in HFD-fed KKAy mice. Note that no significant differences
were observed between +/+ and PACAP/+ mice for any of the
parameters measured, as described (Tomimoto et al., 2004).
EFFECTS ON ISLETS OF VARIOUS SIZES
We next examined which size of islets was decreased by PACAP
in HFD-fed KKAy mice (Figure 1C). In both 5- and 11-month-
old groups, the density of larger (>0.03 mm2) islets was pref-
erentially increased in Ay/+ mice compared with +/+ mice,
and this increase was significantly inhibited in Ay/+:PACAP/+
mice. Since the density of smaller (<0.003 mm2) islets was also
decreased in Ay/+:PACAP/+mice at 5 months of age,we also com-
pared the density of islets sized <0.001 mm2 between Ay/+ and
Ay/+:PACAP/+ mice at that age (Table 1). The result showed an
80% decrease in the density of these tiny islets in Ay/+:PACAP/+
mice, supporting the observation that a marked decrease in
the smaller islets has indeed occurred in Ay/+:PACAP/+ mice.
In contrast, size distribution analysis indicated that the distri-
bution in Ay/+:PACAP/+ mice was almost the same as Ay/+
mice at both ages (5 months old, χ2= 2.33, P = 0.802; 11 months
old, χ2= 1.33, P = 0.932), whereas they were clearly shifted
right compared to +/+ mice (for example, in Ay/+ versus
+/+ mice; 5 months old, χ2= 19.0, P < 0.01; 11 months old,
FIGURE 1 | Quantitative islet histomorphometry of hematoxylin-
eosin-stained pancreatic sections of 5- and 11-month-old F1 mice.
(A) Representative images of pancreatic sections of +/+ (wild-type),
PACAP/+, Ay/+, and PACAP/+:Ay/+ mice stained with hematoxylin-and-eosin
(HE). Arrow heads indicate islets. Scale bar, 500µm. (B,C) Morphometric data
of the HE-stained pancreatic sections. F1 male littermates of 5-month-old
(n=4–6) and 11-month-old (n=7–9) mice were examined. (B) Mean islet size,
density of islets (the number of islets per square millimeter of total pancreatic
area), and the calculated total islet mass in F1 mice. (C) Density of islets of the
indicated size in F1 mice. Data are expressed as the mean+SEM. *P<0.05,
**P<0.01, versus representative control with or without PACAP, #P <0.05,
versus Ay/+ mice, one-way ANOVA followed by the Tukey–Kramer test.
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Table 1 | Parameters of islets in Ay/+ and Ay/+:PACAP/+mice fed a high-fat diet.
Morphological parameters Ay/+ Ay/+:PACAP/+ P -value
HE-stained sections
Density of tiny islets* (/mm2) 2.00±0.32 0.40±0.25 0.004†
Insulin-immunostained sections
Insulin-positive area (% of sections) 4.17±1.07 2.28±0.18 0.127
Density of insulin clusters (/mm2) 1.21±0.16 0.92±0.08 0.159
Frequency of ductal clusters (%) 9.81±0.84 5.88±1.75 0.140
Density of ductal clusters (/mm2) 0.12±0.02 0.05±0.01 0.048†
Mean size of insulin clusters (µm2) 32.6±4.5 25.1±2.2 0.189
Glucagon-immunostained sections
Glucagon-positive area (% of sections) 0.46±0.07 0.49±0.11 0.787
Infiltrated islets# (% of islets) 15.4±2.8 21.3±2.2 0.160
Pancreatic sections prepared from 5-month-old Ay/+ and Ay/+:PACAP/+ mice were stained with hematoxylin-and-eosin (HE, n=5 for each group), anti-insulin anti-
bodies, or anti-glucagon antibodies (n=4 for each group), and were subjected to morphometric analyses. Statistical analyses were performed using an un-paired
Student’s t-test. †Values regarded as statistically significant. *Tiny islets are those of area <0.001 mm2. #Infiltrated islets are those that have glucagon-positive cells
inside, in addition to at their periphery.
χ2= 35.0, P < 0.0001). Collectively, these results suggest that
PACAP overexpression does not affect the overall size distribu-
tion of islets in HFD-KKAy mice, but has clear inhibitory effects
on islet density, particularly in the smaller islets (<0.003 mm2) at
an earlier age (5 months old).
OBSERVATION OF AF-STAINED SECTIONS
To explore the possible changes of islets in Ay/+ and
Ay/+:PACAP/+mice, we used AF staining to examine the degran-
ulation of β-cells, a well known phenotypic change in obese mouse
islets, including those of KKAy mice (Iwatsuka et al., 1970). As
shown in Figure 2A, we observed a clear disappearance of AF
staining in HFD-fed Ay/+mice, but not in+/+mice, at 5 months
of age. However, we unexpectedly observed that AF staining was
obvious in islets of 11-month-old Ay/+mice, implying that a com-
pensatory reaction had occurred. When comparing between Ay/+
and Ay/+:PACAP/+ mice, all islets in all samples at 5 months of
age (n= 5 for each genotypes) lacked AF staining, whereas those
at 11 months of age (n= 3 for each genotype) showed definite
AF staining. These results suggest that an unexpected recovery in
β-cell degranulation could be occurring in HFD-fed KKAy mice,
and that pancreatic PACAP overexpression does not affect either
degranulation, or compensatory re-granulation, of β-cells in this
model.
INTRAPERITONEAL GLUCOSE TOLERANCE TEST
In line with the unexpected recovery in β-cell degranulation,
we previously showed that the glucose disposal in HFD-fed
KKAy mice is unexpectedly enhanced at 11 months of age com-
pared with their age-matched wild-types (Sakurai et al., 2012).
Therefore, we here checked the glucose-induced elevation of
plasma insulin level in the 11-month-old F1 groups (Figure 3).
The results indicated that the insulin level in Ay/+ but not
Ay/+:PACAP/+mice is significantly elevated compared with+/+
and PACAP/+ mice even under fasted state. On the other hand,
the first-phase insulin response (value dividing the insulin level
at 10 min by that at 0 min) was attenuated in both of Ay/+ and
Ay/+:PACAP/+ compared with wild-type mice, but no significant
difference was observed between two groups (The first-phase
insulin response: +/+, 2.73± 0.46; PACAP/+, 2.72± 0.35; Ay/+,
1.16± 0.11; Ay/+:PACAP/+, 1.22± 0.26). These data suggest that
the impaired first-phase insulin response seems to be persis-
tently observed in both Ay/+ and Ay/+:PACAP/+ mice, and
that pancreatic PACAP overexpression showed little effects on the
glucose-induced insulin release at least at 11 months of age.
EFFECTS ON INSULIN OR GLUCAGON CELLS
The above data indicate that phenotypic differences between
the 5-month-old groups were more obvious and are possibly
causative for the changes in 11-month-old groups. Thus, we
next performed detailed analyses on the islets of 5-month-old
Ay/+ and PACAP/+:Ay/+ mice using two adjacent sections
stained with anti-insulin and anti-glucagon antibodies, respec-
tively (Figure 2B). In insulin-stained section, well-stained islets
were commonly observed in both Ay/+ and PACAP/+:Ay/+mice.
Compared with +/+mice, not only enlarged islets but also small
insulin-positive clusters, some of which were located in the ductal
structures (as indicated by arrowheads), were often observed in
these two groups. Glucagon-stained sections revealed an appar-
ent reduction of staining in both Ay/+ and PACAP/+:Ay/+mice
compared with +/+ mice. In addition, some islets showed an
altered localization of glucagon-positive cells (as indicated by
arrows); namely, the cells localized not only peripherally but also
in the central area of the islets. In age-matched +/+ mice, this
was rarely observed and glucagon-positive cells were predomi-
nantly localized at the periphery of the islets. Based on these
observations, a range of parameters were examined (Table 1). In
insulin-stained sections, quantitative analysis revealed a tendency
toward a decrease, but no significant change, in the percent of
insulin-positive area, the density, and the mean size of insulin-
positive clusters between Ay/+ and Ay/+:PACAP/+ mice. How-
ever, the density of ductal insulin-positive clusters was significantly
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FIGURE 2 | Comparative histology of aldehyde-fuchsin, and
anti-insulin or anti-glucagon-stained pancreatic sections of F1 mice.
(A) Pancreatic sections from 5 to 11 months old +/+ (wild-type), Ay/+, and
PACAP/+:Ay/+ mice were stained with aldehyde-fuchsin (AF) reagent to
detect granulated β-cells. Note that a lack of AF staining (degranulation of
β-cells) is observed in islets of Ay/+ and PACAP/+:Ay/+ mice but not in
+/+ mice at 5 months old, but clear staining is generally seen in
11-month-old animals. (B)Two adjacent pancreatic sections from
5-month-old +/+, Ay/+, and PACAP/+:Ay/+ mice were stained with
anti-insulin and anti-glucagon antibodies, respectively. Arrowheads indicate
ductal insulin-positive clusters, whereas arrows denote glucagon
cell-infiltrated islets in which glucagon-positive cells reside inside in
addition to at the periphery of the islet. Note both types of signals were
rarely observed in +/+ mice. Scale bars, 500µm.
decreased (by 58%) in Ay/+:PACAP/+mice compared with Ay/+
mice, whereas the total frequency of ductal clusters was not
significantly different. In glucagon-stained sections, no significant
difference was observed in the percent of glucagon-positive area
and of glucagon cell-infiltrated islets.
DISCUSSION
We examined the morphoregulative roles of PACAP on pancre-
atic islets using a severe and early-onset type II diabetes model
(HFD-fed KKAy mice; Sakurai et al., 2012) over the course of
approximately 1 year. In Ay/+:PACAP/+mice, the significant sup-
pression of islet mass expansion at 11 but not at 5 months of
age (Figure 1B) fits with previous data showing attenuation of
enhanced hyperinsulinemia during 6–10 months of age (Saku-
rai et al., 2012). In contrast, between the age-matched Ay/+
and Ay/+:PACAP/+mice, other morphometric analyses revealed
no significant difference in β-cell granulation, insulin-, and the
glucagon-positive area per pancreatic section, or the distribution
of glucagon-positive cells in islets (Figure 2; Table 1). In addition,
the data in intraperitoneal glucose tolerance test (ipGTT) also sug-
gest that no significant effects of PACAP on the glucose-induced
insulin release. These results therefore suggest that PACAP inhibits
morphological rather than functional changes in islets and thereby
suppresses the increase of hyperinsulinemia in Ay/+:PACAP/+
mice. In addition, taken together with results in ND-fed KKAy
mice (Tomimoto et al., 2004), the present study provides addi-
tional evidence showing morphoregulative roles of PACAP on
pancreatic islets, and establishes the inhibitory effects of PACAP
on compensatory islet mass expansion in type II diabetes.
The present study revealed sustained suppression (at least
between 5 and 11 months of age) of islet density, but not of
mean islet size, in Ay/+:PACAP/+ mice compared with Ay/+
mice (Figure 1B). Taken together with our previous results (Tomi-
moto et al., 2004), these data indicate that PACAP universally and
persistently inhibits the increase of islet density from the early
postnatal period in type II diabetes models. It is unlikely that
HFD and Ay allele-boosted islet enlargement masked PACAP’s
inhibitory effects on mean islet size, because the mean islet size in
5-month-old Ay/+ mice (0.35± 0.06 mm2) was less than half of
that observed in ND-fed KKAy mice (0.80± 0.08 mm2; Tomimoto
et al., 2004). Size-fractionated analyses indicated that the increase
of larger-sized islets in Ay/+ mice is preferentially suppressed by
PACAP at both 5 and 11 months, but also revealed a large decrease
in the smaller islets in Ay/+:PACAP/+ mice at 5 months of age
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FIGURE 3 | Changes in plasma insulin levels in an intraperitoneal
glucose tolerance test (ipGTT) of 11-month-old F1 mice.
Eleven-month-old +/+ (wild-type, n=13), PACAP/+ (n=20), Ay/+ (n=20),
and PACAP/+:Ay/+ (n=27) mice were subjected to ipGTT (Sakurai et al.,
2012). Insulin concentration of each plasma sample was determined.
*P< 0.05 between the indicated groups (two-way repeated-measures
ANOVA).
(Figure 1C; Table 1). These data are consistent with PACAP’s
effects at earlier ages, and suggest PACAP-induced reduction of
small-sized islets as a core phenotype of Ay/+:PACAP/+ mice,
which eventually contributes to the decrease of larger islets and of
islet mass in these mice compared with Ay/+mice.
In Ay/+:PACAP/+ mice fed with ND, we previously showed
that the pancreatic PACAP content and the plasma insulin level
are increased by 3.5- and 2.8-fold of PACAP/+ mice (Tomimoto
et al., 2004), suggesting that Ay allele-related increase in the plasma
insulin boosts the PACAP expression in PACAP/+mice by activat-
ing the human insulin promoter cassette of the transgene construct
(Yamamoto et al., 2003). Although we did not checked the PACAP
content in the present study, the pancreatic content in HFD-fed
Ay/+:PACAP/+ mice could be estimated as more than 10-fold
compared with+/+mice, because their plasma insulin level is 70-
to 100-fold compared with+/+mice (Sakurai et al., 2012) whereas
ND-fed Ay/+:PACAP/+ mice showed 10-fold increase in PACAP
with 2.8-fold increase in plasma insulin compared with+/+mice
(Tomimoto et al., 2004). Since our previous study showed that
the pancreatic PACAP content is 48± 12 pg/mg (Tomimoto et al.,
2004), it could be translated that approximately 10 pM PACAP
exists in pancreas or 1 nM PACAP locally exists around islets
(because PACAP is known to be produced only nearby islets
that corresponds to 1% volume of pancreas). Therefore, if the
PACAP content was increased by more than 10-fold in HFD-fed
Ay/+:PACAP/+mice, it could be activate various intracellular sig-
naling pathway, because higher concentration of PACAP is known
to stimulate Gq-linked pathway in addition to Gs-linked pathway
via binding to PAC1, VPAC1, and VPAC2 receptors (Vaudry et al.,
2009). Thus, it should be noted that further studies are required to
determine the molecular mechanism underlying the phenotypic
changes observed.
Based on current knowledge, the number of small islets (β-cell
clusters) is regulated via diverse processes including differentiation
from ductal precursor cells, trans-differentiation from non-β-cells,
fission or fusion between islets, and replication, hypertrophy, and
apoptosis of the β-cells themselves (Bonner-Weir et al., 2004; Bren-
nand and Melton, 2009). Although further studies on how these
processes may be affected by PACAP should be performed, the
significant decrease in the density of ductal insulin-positive clus-
ters in the context of a normal frequency of these clusters in
the duct (Table 1) strongly suggests that PACAP inhibits duc-
tal precursor-related islet neogenesis in Ay/+:PACAP/+ mice.
If this is the case, it is likely that differentiation from pre-
cursor cells, and/or the cell-fate regulation of newly produced
β-cells from these precursors, are the possible causative mecha-
nisms explaining PACAP-induced reduction of small-sized islets
in Ay/+:PACAP/+mice.
In conclusion, the present study provides additional evidence
for the inhibitory effects of PACAP on pancreatic β-cell mass
expansion, and suggested its possible effects on ductal precursor-
related islet genesis. An increased number of ductal insulin-
positive cells has been reported in pancreatic biopsy samples from
human type II diabetic patients, in which the increased β-cell
mass was suggested to be due to increased islet neogenesis but
not to islet enlargement (Butler et al., 2003). Since these results
imply that the regulation of islet mass depends on species or
disease state-dependent differences, future studies on (postnatal)
islet neogenesis are important for a deeper understanding of islet
homeostasis in type II diabetes, because a number of unrelated
and sometimes contradictory results appear to have accumulated
in this research field.
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